GSK delivers continued strong performance and upgrades 2024 guidance
For media and investors only
Issued: London, UK
Download
(PDF, 1.1MB)
Broad-based performance drives sales, core profit and core EPS growth:
Total Q2 2024 sales £7.9 billion +13%
Vaccines sales +1%, +3% ex COVID.
Shingrix
£0.8 billion...
Zur Pressemeldung auf www.gsk.com